Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement

Agata Kosmaczewska · Jerzy Swierkot · Lidia Ciszak · Aleksandra Szteblich · Agnieszka Chrobak · Lidia Karabon · Anna Partyka · Jacek Szechinski · Piotr Wiland · Irena Frydecka

Received: 24 July 2013 / Accepted: 30 October 2013 / Published online: 13 November 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Systemic immune defects might reflect severely dysregulated control of chronic inflammation related to disease progression. Th17/Treg cell imbalance has been demonstrated to be involved in rheumatoid arthritis (RA) pathogenesis. Despite controversial results, a growing anti-inflammatory role in this process has been recently attributed to Th1 responses. The aim of the study was to estimate the extent of Th1/Th17/Treg imbalance in peripheral blood (PB) of patients with short- and long-term RA in relation to cytokine milieu and its reversal after therapy with methotrexate and/or TNF inhibitors, respectively. Patients with different duration of RA (median 6 vs. 120 months) in the active phase of RA were enrolled in this study. We performed flow cytometric analysis of PB Th1, Th17, and Treg populations together with estimation of serum cytokine concentrations using cytometric bead array. Disease activity was calculated on the basis of clinical and biochemical indices of inflammation (DAS28, ESR, CRP). All parameters were measured and correlated with each other before and after 6 months therapy. Elevated levels of circulating Th17 cells and IL-6 were found in all active patients, of which Th17 cells were down-regulated by the treatment. Significantly reduced Th1 and functional CTLA-4+ Treg cell frequencies as well as Th1 cytokines observed only in progressive RA seemed to be irreversible. Although therapy induced clinical improvement in almost all patients, those with advanced RA remained with signs of inflammation. Our report demonstrates that both the extent of systemic immune abnormalities and their restoration are dependent on duration of the active RA.

Keywords Rheumatoid arthritis · Th1/Th17/Treg imbalance · Cytokines · MTX · TNF inhibitors

Introduction

Rheumatoid arthritis (RA) is one of the most common systemic autoimmune diseases. It is characterized by chronic inflammation in the synovium, resulting in progressive destruction of joints and cartilage. The persistent nature of arthritis strongly suggests immune dysfunctions associated with predominance of the pro-inflammatory responses. It seems that both local and systemic immune abnormalities may be involved in the disease development and evolution. Helper T cells (Th cells) play a major role in initiation and maintenance of the chronic inflammation in RA [1]. According to the cytokine microenvironment, CD4 T cells differentiate toward various pro- and anti-inflammatory subpopulations, including Th1, Th2, Th17, and T regulatory (Treg) cells, playing important roles in the pathogenesis of RA [2].

It has been shown that active RA results from an imbalance in the distribution of pro-inflammatory Th17 and anti-inflammatory Treg cells, which emphasizes the crucial roles of these cells in controlling RA [3]. Th1/Th17/Treg subsets can act as important participants of the complex network of interactions that manage the development and progression of RA, and, what is more important, they can exhibit this action at different stages of the disease with different
intensities. Recent data have suggested interferon-gamma (IFN-\(\gamma\)) and/or interleukin-2 (IL-2) to be protective rather than pro-inflammatory cytokines that could be involved in the down-regulation of RA-related chronic inflammation [4, 5]. In light of the controversial results, the exact impact of Th1 cell responses on Th17/Treg cell systemic distribution in RA remains uncertain [6].

Therefore, we performed a comparative analysis of Th1/Th17/Treg cell distribution in relation to cytokine milieu in peripheral blood (PB) of patients divided into two groups with regard to RA duration (early and advanced stages of RA). Then, we evaluated modifications of studied parameters after 6 months of therapy with methotrexate (MTX) and/or tumor necrosis factor inhibitors (iTNF). We also correlated the results with clinical and laboratory markers of inflammation (DAS28, CRP, ESR) at each time point tested. All results were compared to those obtained in healthy controls.

**Patients and methods**

**Ethics statement**

The study was approved by the Ethics Committee at Wroclaw Medical University, Poland. Written informed consent was obtained from each patient and healthy donor after a full explanation of the procedure, according to the Declaration of Helsinki.

**Patients**

The main characteristics of RA patients are summarized in Table 1. Forty-four patients with RA fulfilling the 1987 diagnostic criteria of the American Rheumatism Association (ARA) [7] and 13 healthy volunteers were included in the study. Eight patients were excluded from the analysis due to irregular reporting to follow up visits and incomplete data regarding activity of the disease and adverse effects. In the final study, 19 patients received oral MTX at a dose of 15 mg per week (MTX group); median (interquartile range) RA duration was 6 months (3–16 months). The other 17 were treated with recommended doses of TNF-\(\alpha\) inhibitors (infliximab (n = 11), adalimumab (n = 2), or etanercept (n = 4) (iTNF group); median RA duration was 120 months (60–160 months). One of the inclusion criteria was active form of the disease established on the basis of clinical and biochemical indices of inflammation, such as the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and calculation of the disease activity score (DAS28); for MTX treatment DAS28 > 3.2, and for iTNF administration DAS28 > 5.1. Based on the statistically significant differences in the median active disease duration and DAS28 score either before or after the treatment between the two groups, iTNF patients were assigned to the progressive form of the disease.

For biologics to be used, treatment failure with at least two traditional disease-modifying antirheumatic drugs (DMARDs) including MTX was required. Thus, all iTNF patients had received MTX in the past history; 13 out of 17 patients were still receiving MTX when iTNF therapy was started. Because of the disease activity, patients were allowed to continue treatment with DMARDs, including MTX, sulphasalazine, glucocorticoids, and nonsteroidal anti-inflammatory drugs, if the treatment regimen was not modified 4 weeks before the study. Based on the efficacy of the therapy, the clinical improvement of RA was established according to the response criteria suggested by the European League Against Rheumatism (EULAR), if reduction of DAS28 was >0.6 (moderate efficacy) or even >1.2 (good efficacy)[8]. Accordingly, at least partial improvement was achieved in 14 (82.35 %) and 19 (100 %) patients treated with iTNF and MTX, respectively. Blood samples were collected just before and after 6 months of the therapy. Healthy individuals were free of the following events: inflammatory syndrome (CRP < 0.5 mg/dL), steroid or immunosuppressive therapy, acute or chronic infectious diseases, other autoimmune diseases, and cancers. The controls were matched with patients for age and sex.

**Cell preparation, culture conditions, and flow cytometry**

Peripheral blood mononuclear cells (PBMCs) were isolated by buoyant density-gradient centrifugation on Lymphophlot (Biotest, Germany) from 40 ml of freshly drawn peripheral venous blood (PB). Because incubation with phorbol 12-myristate 23-acetate (PMA) triggers internalization and degradation of the CD4 molecule, which would affect the identification of Th1 (CD4+IL-17-IFN-\(\gamma\)+) and Th17 (CD4+IFN-\(\gamma\)-IL-17+) cells [9], CD4+ T cells were negatively separated before cytokine staining. CD4+ T cells purified by magnetic cell sorting (Miltenyi Biotec) were then stimulated with 25 ng/ml PMA and 1 \(\mu\)g/ml of ionomycin (Ion) (Sigma-Aldrich) in the presence of 10 \(\mu\)g/ml of brefeldin A (BFA, protein transport inhibitor) for 4 h at 37 °C in a humidified atmosphere containing 5 % CO2. For analysis of Tregs (CD4+FoxP3+ T cells) as well as CTLA-4+Tregs, PBMCs were aliquoted into tubes directly after isolation for further staining performed as follows: the cells were stained with anti-CD3/FITC (clone UCHT1; BD Pharmingen), anti-CD4/PerCP (clone SK3; BD Pharmin gen) or anti-CD4/FITC (clone SK3; BD Pharmingen), and CTLA-4/PE-Cy monoclonal antibodies (mAbs)
Table 1  Patients’ characteristics before and after therapy with MTX and/or iTNF

| MTX therapy group | iTNF therapy group | MTX versus iTNF therapy ($P$ value) |
|-------------------|-------------------|-----------------------------------|
| Before | After | $P$ value | Before | After | $P$ value | Before | After | $P$ value |
| Number ($n$) | 19 | 17 | 0.0000001 | 6.1 | 4.7 | 0.00007 | 0.02 | 0.0001 | 0.0000001 |
| MTX$^a$ treatment $+/-$ | 19/19 | 13/17 | 0.00006 | 14.0 | 7.0 | 0.0003 | 0.03 | 0.0002 |
| INF$^b$ treatment $+/-$ | | 11/17 | | | | | | |
| ADA$^c$ treatment $+/-$ | 2/17 | | | | | | | |
| ETA$^d$ treatment $+/-$ | 4/17 | | | | | | | |
| Sex (F/M) | 12/7 | 14/3 | | | | | |
| Age (years) | 55.0 [41.5–67.0] | 52.5 [46.0–55.0] | | | | |
| Duration (months) | 6.0 [3.0–15.9] | 120.0 [60.0–160.0] | | | 0.0000001 |
| DAS 28 | 5.8 [4.9–6.2] | 3.5 [3.1–4.0] | 0.0000001 | 6.1 [5.7–6.9] | 4.7 [4.0–5.8] | 0.00007 | 0.02 | 0.0001 |
| TJC | 10.0 [8.0–14.0] | 2.0 [1.0–4.0] | 0.0009 | 14.0 [11.0–18.0] | 7.0 [5.0–11.0] | 0.0003 | 0.03 | 0.0002 |
| SJC | 6.0 [4.0–10.0] | 1.0 [0.0–2.0] | 0.00009 | 8.5 [6.0–13.0] | 4.0 [3.0–6.0] | 0.0003 | NS | 0.0002 |
| VAS (mm) (%) | 60.0 [47.0–70.0] | 23.0 [10.0–30.0] | 0.0000001 | 67.5 [63.0–80.0] | 40.0 [25.0–60.0] | 0.0007 | 0.02 | 0.001 |
| ESR (mm/h) | 28.0 [17.5–39.0] | 18.0 [12.0–26.0] | 0.006 | 26.0 [19.0–44.0] | 21.0 [17.0–33.0] | NS | NS | NS |
| CRP (mg/L) | 11.0 [6.5–19.0] | 3.6 [2.1–6.8] | 0.005 | 15.8 [10.0–31.0] | 8.0 [4.1–42.0] | NS | NS | 0.05 |
| Leukocytes (G/L) | 7.7 [6.0–9.3] | 6.7 [4.9–7.9] | 0.009 | 9.6 [6.8–11.5] | 8.9 [6.1–10.6] | NS | NS | 0.05 |
| Platelets (x10$^9$/L) | 304.0 [220.0–348.0] | 249.0 [200.0–298.0] | 0.02 | 294.0 [260.0–377.0] | 285.5 [242.00–353.00] | NS | NS | NS |
| Hb (g/dL) | 12.2 [11.8–13.5] | 12.7 [11.8–14.0] | NS | 12.7 [11.9–12.9] | 12.9 [12.4–13.5] | NS | NS | NS |
| % CD4$^+$ lymphocytes in total T cells | 63.9 [52.6–78.2] | 59.7 [50.4–63.3] | NS | 71.9 [60.2–77.4] | 67.4 [59.9–69.6] | NS | NS | NS |

DAS28, disease activity score rated by the 28 joint count; TJC, tender joint count; SJC, swollen joint count; VAS, general health patient; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

$^a$ MTX: up to 25 mg/week orally
$^b$ INF: 3 mg/kg body weight; i.v. infusion at weeks: 0, 2, and 6, and every 8 weeks thereafter
$^c$ ADA: 40 mg every other week; s.c.
$^d$ ETA: 50 mg every week; s.c.
For intracellular staining, the cells were fixed and permeabilized with BD Permeabilizing Solution 2 (Becton–Dickinson) according to the manufacturer’s instructions with subsequent incubation with anti-IFN-γ/FITC (clone 25723.11; BD Pharmingen), anti-IL-17/PE (clone eBio64DEC17; eBioScience), anti-human FoxP3/PE mAbs (clone 259D/C7; BD Pharmingen), or fluorochrome-labeled isotypic control mAbs for 30 min at room temperature in the dark. Directly after immunostaining, the cells were washed and analyzed by flow cytometry using a FACScan cytometer equipped with Cell Quest software (BD Bioscience).

RNA isolation and real-time PCR (RT-PCR)

Total RNA was extracted from CD4+ T cells using RNeasy columns (Qiagen, Hilden, Germany), subjected to DNase I treatment according to the manufacturer’s protocols and immediately 800 ng of RNA was reverse transcribed using the iScript cDNA Synthesis Kit (Biorad, Hercules, CA, USA). The mRNA levels of human IL-17A, FoxP3, INFγ, and β2 microglobulin (β2M) were analyzed by quantitative real-time PCR using primers and probes from Applied Biosystems (Hs00174383_m10, Hs01085832_m1, Hs00989291_m1, and Human β2M, respectively). All the samples were analyzed using the 7300 Real-Time Instrument (Applied Biosystems). To calculate relative expression, all results were analyzed according to the ΔCt method using β2M as a reference gene.

Cytokine assays

Cytokines (IL-6, IL-2, IFN-γ, TNF-α, and IL-17) were measured in patients’ and controls’ sera by a flow cytometric bead array using human cytokines kits of the BD™ CBA Human Soluble Protein Flex Set system (Becton–Dickinson) and analyzed on a FACSCalibur flow cytomter (Becton–Dickinson), as recently described [10].

Statistical analysis

One-way ANOVA test was used to determine significant differences between groups. Spearman’s test was used for correlation analysis. The Wilcoxon signed rank test was used to compare paired patients before and after the treatment. Results were considered statistically significant when \( P \leq 0.05 \). Data are presented as median (interquartile range). Statistica’99 Edition was used in the statistical calculations.

Results

Pre-treatment distribution of PB Th1, Th17, and Treg cell population

In order to determine the relationship between the duration of active RA and distribution of anti- and pro-inflammatory Th cell subpopulations in PB, we assessed the proportion of Th1, Th17, and Treg cells in patients before MTX and/ or iTNF administration. We did not find any significant differences in the relative mRNA expression of IFN-γ, IL-17, and FoxP3 between all studied groups (Table 2). Both groups of RA patients exhibited significantly and similarly increased Th17 populations compared to controls (Figs. 1a, 2a). Only iTNF patients possessed a reduced Th1 cell population compared to others. There were no differences in Th1 cell frequency in PB between MTX patients and controls (Figs. 1a, 2a). The proportions of circulating Treg cells as well as those co-expressing the suppressor CTLA-4 molecule (CTLA-4+ Tregs) were lower in the iTNF group than in controls, in contrast to the similar values in the MTX group and healthy subjects (Figs. 1b, c, 2c, d).

Pre-treatment serum cytokine profile

We also verified whether the different duration of active RA might modify the serum cytokine profile, thus affecting
CD4 Th cell differentiation. All RA patients showed higher serum concentrations of IL-6 than controls, with the highest values in the iTNF group (Fig. 3a). Solely the iTNF group possessed lower levels of Th1 cytokines, more pronounced considering IL-2 (Fig. 3b, c). In contrast, no differences in Th1 cytokine values between MTX patients and controls.
were seen (Fig. 3b, c). Serum TNF-α and IL-17 reached similar levels in all patients and controls (Fig. 3d, e).

Post-treatment distribution of PB Th1, Th17, and Treg cell population

Next, we tried to explore the relevance of therapy in the studied subpopulations depending on RA duration. A decrease in the PB Th17 cell population after the treatment in all patients, but more vigorous in MTX patients, was found (Fig. 2b). Nevertheless, the iTNF treatment up-regulated IL-17 gene activity, resulting in higher relative expression of IL-17 mRNA in CD4+ T cells of iTNF patients compared to the MTX group and to controls (Table 2). Accordingly, Th17 cells were expanded to twofold higher levels in PB of patients compared to controls; however, the differences were not statistically significant (Fig. 2b). Although the levels of relative mRNA expression of both IFN-γ and FoxP3 did not differ markedly between studied groups (Table 2), the iTNF patients maintained a systemic Th1 cell loss after the treatment (Fig. 2a). In contrast, MTX patients demonstrated a similar Th1 cell population compared to controls (Fig. 2a). Therapy changed, albeit nonsignificantly, the frequency of PB Treg cells in all RA patients, reversing, in consequence, defective Treg proportions in the iTNF group (Fig. 2c). Nevertheless, Tregs from these patients maintained CTLA-4 expression in the diminished proportions of cells compared to healthy corresponding Treg cells (Fig. 2d).

Post-treatment serum cytokine profile

We assessed serum cytokine modification under the different therapeutic interventions regarding RA duration as well. A decline of serum IL-6 concentrations was seen only in the MTX group. Nevertheless, its level was not normalized in all patients (Fig. 3a). Among the patients, IL-6 concentration was highest in the iTNF group. IL-2 and IFN-γ remained at lower concentrations in sera from iTNF patients (Fig. 3b, c). In contrast, increased IL-2 levels were found only in the MTX group (Fig. 3b). Neither MTX nor iTNF treatment changed TNF-α or IL-17 concentrations in RA, their levels being comparable to those seen in controls (Fig. 3d, e).

Correlation between clinical, immune, and laboratory parameters in patients at different stages of RA

We analyzed correlations among the proportion of examined T helper subpopulations (Th1, Th17, and Treg) in PB, serum soluble factors (IL-6, IL-2, IFN-γ, TNF, and IL-17), and clinical and/or laboratory features of RA in all studied groups of patients before and after the treatment. We found several statistically significant relationships among studied parameters, of which the most interesting comparisons have been presented in Table 3.
Discussion

Our present work strongly demonstrates that RA patients present an imbalance in CD4 T cell subsets’ distribution in PB, more pronounced in those with the most advanced disease, suggesting the impact of disease progression on subsequent changes. Considering CD4 T cell subpopulations, a common disorder found in all RA patients irrespective of the disease duration was expansion of Th17 cells in circulation. This observation is in accordance with previous reports \[11–20\] and confirms that Th17 is a key effector cell in the pathogenesis of RA \[21\]. Its strong pro-inflammatory action has been attributed to secretion of IL-17 and, to a lesser extent, TNF-α and IL-6 \[22\]. In addition, IL-17 induces the production of TNF-α, IL-6, and IL-1beta in numerous cell types \[23\] and can act in synergy with TNF-α to stimulate the production of pro-inflammatory cytokines, chemokines and metalloproteases from synovial fibroblasts, leading finally to cartilage loss \[24, 25\]. Moreover, during the course of RA it can promote osteoclastogenesis and bone absorption \[26\].

On the other hand, Th17 differentiation is dependent on IL-6 abundantly expressed in the inflamed joints and PB in patients with active RA, which emphasizes their reciprocal regulation \[27, 28\]. Permanently augmented concentrations of IL-6 in sera from RA patients \[29\] have been also confirmed in our study even after the biologic treatment. Consequently, we observed significantly enhanced activity of the IL-17 gene in the same patients. It should be stressed, however, that only patients with relatively short duration of active RA exhibited a higher potential for reversion of dysregulated IL-6 and Th17 cells as well as for reduction in disease activity compared to those with advanced disease.

### Table 3 Correlations between clinical, immune, and laboratory parameters in RA patients

| Correlated parameters   | MTX treatment |  |  | iTNF treatment |  |  |
|-------------------------|---------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                         | Before | After | Before | After | Before | After |
| IL-6/CRP                | P = 0.015 | P = 0.008 | P = 0.04 | P = 0.0004 |  |  |
|                         | r = 0.61 | r = 0.62 | r = 0.53 | r = 0.74 |  |  |
| IL-6/Th1                | NS | NS | P = 0.05 | NS |  |  |
|                         |  |  | r = −0.45 |  |  |  |
| IL-6/Th17               | NS | NS | P = 0.04 | NS |  |  |
|                         |  |  | r = 0.66 |  |  |  |
| IL-6/DAS28              | NS | NS | NS | P = 0.02 |  |  |
|                         |  |  |  | r = 0.54 |  |  |
| Th1/DAS28               | NS | NS | P = 0.03 | NS |  |  |
|                         |  |  | r = −0.50 |  |  |  |
| Th1/CRP                 | NS | NS | P = 0.05 | NS |  |  |
|                         |  |  | r = −0.45 |  |  |  |
| Th1/Th17                | NS | NS | P = 0.04 | NS |  |  |
|                         |  |  | r = −0.69 |  |  |  |
| Th1/Treg                | NS | NS | P = 0.05 | NS |  |  |
|                         |  |  | r = 0.45 |  |  |  |
| IL-2/CRP                | NS | P = 0.007 | NS |  |  |
|                         |  | r = −0.92 |  |  |  |
| IL-2/CTLA-4+Treg        | NS | NS | P = 0.02 | NS |  |  |
|                         |  |  | r = 0.71 |  |  |  |
| Treg/CRP                | NS | NS | P = 0.002 | NS |  |  |
|                         |  |  | r = −0.87 |  |  |  |
| CTLA-4+Treg/CRP         | NS | NS | NS | P = 0.02 |  |  |
|                         |  |  |  | r = −0.64 |  |  |
| Th17/Treg               | NS | NS | P = 0.05 | NS |  |  |
|                         |  |  | r = −0.65 |  |  |  |
| CTLA-4++Treg/Th17       | P = 0.01 | P = 0.05 | NS | P = 0.04 |  |  |
|                         | r = −0.61 | r = −0.45 |  | r = −0.44 |  |  |
| TNF/Treg                | NS | NS | P = 0.05 | NS |  |  |
|                         |  |  | r = −0.65 |  |  |  |
| TNF/IL-17               | P = 0.000001 | P = 0.000001 | P = 0.0002 | P = 0.01 |  |  |
|                         | r = 0.95 | r = 0.95 | r = 0.76 | r = 0.58 |  |  |
| IL-2/IFN                | NS | NS | NS | P = 0.05 |  |  |
|                         |  |  |  | r = 0.62 |  |  |

NS nonsignificant
Of note, no significant changes were observed in the serum levels of TNF-α and IL-17 in all patients at each time point tested, which was an unexpected observation when we consider their strong pro-inflammatory action and fundamental role in RA development [30]. Previous assessments demonstrated no significant increment [13, 14, 31] or, alternatively, an increase in TNF-α or IL-17 in sera from RA patients [11, 12, 30, 32–35]. It seems reasonable that unstable in vitro activity of TNF-α and IL-17 probably resulting from the relatively short half-life of both cytokines might affect their detectable levels found in our experiments [35]. Since IL-6 has a much longer half-time and is closely and positively interrelated with TNF-α and IL-17 in all studied patients, it appears to reflect intrinsic concentrations of both factors, thus being a better disease marker for measurements in patients’ sera [35].

It should be emphasized that progression of RA seems to correspond with many additional alterations in systemic distribution of T helper subsets studied, as was recently suggested [36]. In particular, we demonstrated that during disease evolution PB Th17 expansion was accompanied by diminished Th1 and Treg cell populations, indicating a profound imbalance in pro- and anti-inflammatory T cells in the periphery. We found that changes in the intracellular expression of IFN-γ, IL-17, and FoxP3 transcription factor seen in PB CD4+ T cells from untreated RA patients might be due to the post-transcriptional alterations rather than the markedly disturbed gene activity. Recently, other investigators have reported dysregulated Treg numbers in the periphery in active RA. Some studies demonstrated decreased [37], unchanged [38], or increased percentages of peripheral Tregs in the course of RA [39]. All these discrepancies may result from the differences in determination of Treg unique phenotype. Furthermore, since the CTLA-4 molecule plays a crucial role in Treg function, our study showing decreased CTLA-4+ Treg frequency in PB in advanced RA points to the possibility of Treg functional impairment especially during disease progression [38, 40]. However, the overall reasoning has to be cautious due to the lack of Treg functional assay in our experiment.

The current study clearly showing a systemic loss of Th1 cell population in progressive RA corresponds with some recent observations on a relation of RA activity/progression with Th1 defective response in PB [41, 42]. However, several previous reports showed contradictory results; some of them described increased [15, 35] or unchanged frequencies of Th1 cells in circulation in the course of RA [43, 44]. These discrepancies may be related to the fact that examined patients exhibiting a systemic decrement of Th1 cell frequency had much longer duration of the active disease, which may indicate the impact of RA progression on Th1 lineage restriction. In contrast, patients with relatively short-term disease assigned to MTX therapy exhibited no changes in the numbers of PB Th1 cells, which was consistent with past studies [43, 44].

Mechanisms underlying the decreased proportion of peripheral Th1 cells in advanced RA are not fully understood, but the influence of the serum cytokine profile affecting CD4 Th cell differentiation should have been taken into account. Since we found that the levels of cytokines exerting inhibitory activity toward Th1 differentiation, including IL-6 and IL-17 [45, 46], did not differ significantly between examined groups of patients, it seems that other factors may affect the Th1 lineage in progressive RA rather than dysregulated differentiation. In fact, a few previous reports suggested selective migration of Th1 cells from PB into inflamed joints in active RA [41, 47, 48], which might result in altered Th1 frequencies in PB. It cannot be excluded that the strength of this process corresponds with disease activity/severity, since we found that solely the iTNF group of patients remained with a systemic Th1 defect inversely correlated, in addition, with stably increased CRP levels even after the therapy. Another explanation for PB Th1 cell down-regulation in progressive RA is the possible impact of long-term use of some drugs capable of interfering with the Th1 phenotype, such as MTX, iTNF, and/or statins [49–51]. It is, however, difficult to distinguish between the role of pharmacological treatment per se and the severity/duration of RA in decrement of Th1 cell percentages as both parameters seem to be closely interrelated.

Consequently, the lower proportion of circulating Th1 cells was accompanied by diminished serum levels of Th1 cytokines, including IL-2 and IFN-γ. In fact, qualitative impairment of PB effector T cells, especially those with Th1 phenotype, was attributed to chronic exposure to stimulation via TNF-α [52]. Consistently with us, a deficit in serum Th1 cytokines in active RA and/or their negative relationship with disease activity have also been reported [34, 35, 41, 42, 53]. It is worthy of note, however, that our results contradict several previous reports showing increased or unchanged circulating Th1 cytokines in RA [12, 32, 33, 35] only in the part considering patients with the most advanced disease. Furthermore, in the same group of patients, we did not observe any influence of long-term iTNF treatment on changes in PB Th1 cell responses, as they entered the study with compromised baseline Th1 cytokine values. In some experiments, involving patients with relatively early stages of RA with no Th1 defects, a down-regulating effect of iTNF was observed [15, 50].

Given that IL-2 was demonstrated to be critical for the differentiation of Tregs from naïve CD4+ T cells, the lack of significant difference in Treg frequency between the MTX group and iTNF group despite evident decrease in serum IL-2 levels in the latter was, in fact, an unexpected
finding. Nevertheless, it seems to be consistent with the recent studies showing an important role of IL-2 in the maintenance of homeostasis of the circulating Treg cell compartment \[54\], consisting of both the natural CD62L\(^{hi}\) and induced CD62L\(^{lo}\) FoxP3+ Tregs \[55\]. It has been shown that natural Tregs are more sensitive to changes in the level of IL-2 than induced Treg cells \[56\]. In particular, Goudy et al. \[56\] demonstrated that IL-2 shortage could correlate with a decreased proliferative status of natural Tregs in a mouse model of autoimmunity, but not with induced Tregs, despite similar levels of CD25 and CTLA-4 surface expression between the arms. Therefore, an obviously reduced expression of serum IL-2 found in iTNF patients with progressive disease might dysregulate the ratio of the CD62L\(^{hi}\) to CD62L\(^{lo}\) Tregs, which exert different suppressive potential, thus resulting in qualitative rather than quantitative differences in the FoxP3+ Treg pool detected in their circulation.

In addition to the generation and survival of Treg cells, inhibition of Th17 polarization appears to be an important function of IL-2; hence this Th1 cytokine is capable of controlling the Th17/Treg balance in the periphery \[5, 57, 58\]. In fact, an affected Th1 response has been suggested to shift the T cell homeostasis from a Treg-mediated tolerant state to Th17-mediated active inflammatory conditions \[4, 57\]. An increase in inflammatory disease activity in the presence of impaired Th1 responses has been well documented \[6, 59–61\]. Therefore, an increased Th17/Treg ratio in PB of the most advanced RA patients examined, which corresponded with either down-regulation of Th1 cells or laboratory signs of inflammation strengthens the suggestion that those systemic alterations may be, in fact, an immune signature of disease progression. In this context, we observed a Th1 protective response only in patients with short-term RA. Additional correlations among studied subpopulations and markers of inflammation seen in advanced RA emphasize a major role of systemic Th1 alterations in the management of Th17/Treg imbalance at this stage of the disease.

Herein, we also demonstrated that the main immune advantage of the therapy with MTX and/or iTNF in examined RA patients was the reversion of Th17 cell expansion. Available data concerning the effect of the different therapeutic interventions on the Th17 cell population are still confusing. Several studies have shown an unchanged \[13, 15, 20\] or, alternatively, a decreased Th17 frequency following treatment with MTX and/or iTNF \[13–16, 19, 20\], and the latter findings are in accordance with the current study. Similarly to the recent work \[20\], monotherapy with MTX was able to effectively limit the Th17 population only in the patients with early disease. In general, our study showed that the treatment used exhibited the most beneficial effect mainly for patients at a relatively early stage of the disease, as Th17 expansion was the only Th cell alteration seen in those patients’ circulation. As regards the patients with progressive disease, they required biologic treatment to be used. All the reports consistent with ours \[13–16, 19, 20\] strengthen the conclusion that the effectiveness of iTNF therapy concerning Th17 expansion should be evaluated not earlier than 12 weeks after biologics usage irrespective of the MTX administration.

Although the therapy with iTNF partially corrected the Th17/Treg imbalance seen in the most advanced RA, which was in line with other reports \[15\], it was accomplished also due to affecting the Th17 population, but not by evident Treg frequency improvement. Nonetheless, systemic Th1 loss and compromised Treg function, as evaluated by sustained lower PB Th1 and CTLA-4+ Treg frequency in the iTNF group despite the treatment, seemed to be irreversible phenomena in progressive disease. Although restoration of Treg suppressive activity after iTNF therapy has been previously reported, this improvement was only transient or restricted to the patients responding to the treatment \[38\]. We suggest that the compromised influence of iTNF on the proportion of functional CTLA-4+ Tregs in progressive RA is associated with an irreversible deficit in Th1 cytokine level. In particular, serum IL-2 shortage might be responsible for persistent qualitative alterations within Treg pool, when we consider a crucial role of IL-2 either in the maintenance of Treg compartment homeostasis \[56\] or in CTLA-4 expression in T cells \[62\]. While it is true that CTLA-4 contributes to the suppressive function of Tregs \[40\], it cannot be used as a single marker to define the functional status of a Treg; hence its functional significance should be considered with caution.

In conclusion, our study shows that both the degree of the immune alterations in PB of RA patients and their reversal after different therapeutic interventions depend on the duration of the active disease. Patients with relatively short-term disease possess a higher capacity for reversion of the studied abnormalities. In contrast, patients with progressive and long-term RA remain with much immune dysregulation managed by Th1 systemic defects even after iTNF treatment. Therefore, patients at early stages of active RA would certainly benefit from iTNF administration rather than those with the most advanced disease. In this context, new approaches based on restoration of Th1 protective responses capable of controlling the balance between Th17 and Tregs would be of interest as another target for the treatment of progressive RA. Recently, such a study concerning the influence of exogenous IL-2 on the balance in Th1, Th17, and Treg cell distribution in the different stages of RA was performed in our laboratory (data to be published).
Acknowledgments This work was supported by a Grant from the National Science Centre (Poland); Grant No. N N402 244935. We also would like to thank Mrs. Anna Tomkiewicz for excellent technical assistance.

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Weyand CM, Goronzy JJ (1997) Pathogenesis of rheumatoid arthritis. Med Clin N Am 81:29–55
2. Toh ML, Miossec P (2007) The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 19:284–288
3. Afzali B, Lombardi G, Lechler RI, Lord GM (2007) The role of T helper transplantation and autoimmunity disease. Clin Exp Immunol 148:32–46
4. Kelchtermans H, De Klerck B, Mitera T et al (2005) Defective CD4+CD25+ regulatory T cell function in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther 7:R402-R415
5. Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmunity disease by IL-2 neutralization. J Exp Med 201:723–735
6. Rosloniec EF, Latham K, Guedez Y (2002) Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis Res 4:333–336
7. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Rheumatism 31:315–324
8. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964–975
9. Hennessy B, North J, Deru A, Llewellyn-Smith N, Lowdell MW (2001) Use of Leu3a/3b for the accurate determination of CD4 subsets for measurement of intracellular cytokines. Cytometry 44:148–152
10. Nitsch SM, Pries R, Wollenberg B (2007) Head and neck cancer triggers increased IL-6 production of CD34+ stem cell from human cord blood. In vivo 21:493–498
11. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL (2012) Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 32:2731–2736
12. Wang W, Shao S, Jiao Z, Guo M, Xu H, Wang S (2012) The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 32:887–893
13. Shen H, Xiao L, Zhong Y, Xiao W (2010) Inflaximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis. J Invest Med 58:905–908
14. Yue C, You X, Zhao L et al (2010) The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 30:1553–1557
15. Lina C, Conghua W, Nan L, Ping Z (2011) Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J Clin Immunol 31:596–605
16. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2001) Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 13:R126
17. Chen J, Li J, Gao H et al (2012) Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol 2012:535361
18. Al zabir S, Abraham SM, Taher TE et al (2012) Incomplete response of inflammatory arthritis to TNF-alpha blockade is associated with the Th17 pathway. Ann Rheum Dis 71:1741–1748
19. McGovern J, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR (2012) Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor alpha antibody therapy. Arthritis Rheum 64:3129–3138
20. Szalay B, Vasarhelyi B, Cseh A et al (2013) The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol. doi:10.1007/s10067-013-2352-x
21. Van Hamburg JP, Asmawidjaja PS, Davlaer N et al (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63:73–83
22. Bettelli E, Oukka M, Kuchroo VK (2007) Th17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345–350
23. Miossec P (2007) Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. Arthritis Rheum 56:2111–2115
24. Van Bezooyen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergizes with tumor necrosis factor alpha to induce cartilage degradation in vitro. Ann Rheum Dis 61:870–876
25. Moran EM, Mullan R, McCormick J et al (2009) Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumor necrosis factor-alpha, oncostatin M and response to biologic therapies. Arthritis Res Ther 11:R113
26. Sato K, Suematsu A, Okamoto K et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682
27. Acosta-Rodrigez RV, Rivino L, Geginat J et al (2007) Surface phenotype and antigen specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8:639–646
28. Houssiau FA, Devogelaer JP, Van Damme J, Devleeschouwer CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31:784–788
29. Knausen LS, Hetland ML, Johansen JS et al (2009) Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment with etanercept and methotrexate or etanercept alone in patients with active rheumatoid arthritis despite methotrexate therapy. Biomark Insights 4:91–95
30. Hussein MR, Fathi NA, El-Din AIME et al (2008) Alterations of the CD4+, CD8+ T cell subsets, interleukins-1β, IL-10, IL-17, tumor necrosis factor-α and soluble intercellular adhesion molecule-1 in rheumatoid arthritis and osteoarthritis: preliminary observations. Pathol Oncol Res 14:321–328
31. Macias I, Garcia-Perez S, Ruiz-Tudela M et al (2005) Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-alpha blockade in patients with rheumatoid arthritis. J Rheumatol 32:2102–2108
32. Meyer PW, A, Hodkinson B, Ally M et al (2010) Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010:158514
33. Marti L, Golmia R, Golmia APF et al (2009) Alterations in cytokine profile and dendritic cell subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann NY Acad Sci 1173:334–342

34. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J (2001) Serum cytokines of different histological variants of rheumatoid arthritis. J Rheumatol 28:1211–1217

35. Tukaj S, Kotlarz A, Jozwik A et al (2010) Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostics markers. Acta Biochim Pol 57:327–332

36. De Paz B, Alperi-Lopez M, Ballina-Garcia FJ, Prado C, Gutierrez C, Suarez A (2010) Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J Rheumatol 37:2502–2510

37. Lawson CA, Brown AK, Bejarano V et al (2006) Early rheumatoid arthritis is associated with a deficit in the CD4+CD25 high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45:1210–1217

38. Ehrenstein MR, Evans JG, Singh A et al (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 200:277–285

39. Han GM, O’Neil-Andersen NJ, Zurier RB, Lawrence DA (2008) CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol 253:92–101

40. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR (2008) Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 105:19396–19401

41. Kawashima M, Miossec P (2005) mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. J Clin Immunol 25:209–214

42. van Roon JAG, Verhoef CM, van Roy JLAM et al (1997) Decrease in peripheral type I over type II T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann Rheum Dis 56:656–660

43. Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA (2000) Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27:1128–1135

44. Samson M, Audia S, Janakishvili N et al (2012) Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 64:2499–2503

45. Toh ML, Kawashima M, Hot A, Miossec P, Miossec P (2007) Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis 69:1562–1567

46. Diehl S, Anguita J, Hoffmeyer A et al (2000) Inhibition of Th1 differentiation by IL-6 is mediated by SOCS-1. Immunity 13:805–815

47. van der Graaf WL, Prins APA, Niers TMH, Dijkman BA, van Lier RA (1999) Quantification of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology 38:214–220

48. Yamada H, Nakashima Y, Okazaki K et al (2008) Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67:1299–1304

49. Xingqiang S, Fei L, Nan L et al (2010) Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother 64:463–471

50. Schotte H, Schlutter B, Willeke P et al (2004) Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology 43:960–964

51. Blaschke S, Vierveck V, Schwarz G, Klinger HM, Guerluek S, Muller GA (2009) Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 38:235–239

52. Cope AP, Londei M, Chu NR et al (1994) Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94:749–760

53. Avramescu C, Vere CC, Margaritescu C et al (2005) Cytokine panel in rheumatoid arthritis and correlation with histological patterns of synovitis—active type of disease. Rom J Morphol Embryol 46:87–92

54. Tang Q, Adams JY, Penaranda C et al (2008) Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28:687–697

55. Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33–39

56. Goudy KS, Johnson MC, Garland A et al (2011) Reduced IL-2 expression in NOD mice leads to a temporal increase in CD62L+FoxP3+CD4+ T cells with limited suppressor activity. Eur J Immunol 41:1480–1490

57. Laurence A, Tato CM, Davidson TS et al (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371–381

58. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519–6523

59. Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

60. Malek TR, Yu A, Vincek V, Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17:167–178

61. Irmler IM, Gajda M, Brauer R (2007) Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol 179:6228–6236

62. Perkins D, Wang Z, Donovan C et al (1996) Regulation of CD256 T cell numbers are enriched in the peripheral blood from rheumatoid arthritis patients before and after biologic therapy. J Exp Med 200:277–285